Description

Vidarabine (Ara-A) is a nucleoside analog with potent antiviral properties, primarily used in research and pharmaceutical applications. Its molecular formula is C₁₀H₁₃N₅O₄, and it is derived from the natural nucleoside adenosine by replacing the ribose sugar with arabinose. Vidarabine is known for its inhibitory effects on viral DNA polymerase, making it a critical compound in antiviral research, particularly against herpesviruses.

This high-purity compound is supplied as an anhydrous powder, ensuring stability and consistency for laboratory use. It is ideal for researchers investigating antiviral mechanisms, nucleotide metabolism, and drug development. Vidarabine is also used in cell culture studies and biochemical assays to explore its impact on viral replication and host-cell interactions.

Our product is rigorously tested for quality, with HPLC and NMR verification to guarantee >98% purity. Each batch is accompanied by a Certificate of Analysis (CoA) to ensure compliance with research standards. Store at -20°C in a dry, dark environment to maintain stability.

Properties

• CAS Number: 5536-17-4
• Complexity: 335
• IUPAC Name: (2R,3S,4S,5R)-2-(6-aminopurin-9-yl)-5-(hydroxymethyl)tetrahydrofuran-3,4-diol
• InChI: InChI=1S/C10H13N5O4/c11-8-5-9(13-2-12-8)15(3-14-5)10-7(18)6(17)4(1-16)19-10/h2-4,6-7,10,16-18H,1H2,(H2,11,12,13)/t4-,6-,7+,10-/m1/s1
• InChI Key: OIRDTQYFTABQOQ-UHTZMRCNSA-N
• Exact Mass: 267.09675391
• Molecular Formula: C10H13N5O4
• Molecular Weight: 267.24
• SMILES: C1=NC(=C2C(=N1)N(C=N2)[C@H]3[C@H]([C@@H]([C@H](O3)CO)O)O)N
• Topological: 140
• Monoisotopic Mass: 267.09675391
• Physical Description: Vidarabine is a white to off-white crystalline powder.
• Color/Form: Crystals from water
• Melting Point: 500 to 518 °F
• Solubility: >40.1 [ug/mL]
• Stability/Shelf Life: Vidarabine ophthalmic ointment should be stored at a temperature less than 40 °C, preferably between 15-30 °C; freezing should be avoided.
• Synonyms: Vidarabine, 5536-17-4, Adenine arabinoside, Ara-A, Vira-A, Arabinosyladenine, Spongoadenosine, Araadenosine, Arasena-A, 9-beta-D-Arabinofuranosyladenine, Vidarabin, Vidarabine anhydrous, Arabinosyl adenine, Arabinoside adenine, Vidarabina, Vira ATM, Vidarabinum, Vidarabina [DCIT], Vidarabine [INN], 9-beta-Arabinoadenosine, beta-D-Arabinosyladenine, 9beta-D-Arabinofuranosyladenine, Adenine-beta-D-arabinofuranoside, NSC-404241, Vidarabinum [INN-Latin], Vira A, Vidarabine (JAN), 9-BETA-D-ARABINOFURANOSYL-ADENINE, 9-Arabinosyladenine, Armes (TN), Vidarabine, anhydrous, beta-D-Arabinofuranosyladenine, 9-beta-D-arabinofuranosyl-9H-purin-6-amine, CCRIS 3383, Adenine beta-D-arabinofuranoside, HSDB 6514, Adenine-9-beta-D-arabinofuranoside, Adenine, 9beta-D-arabinofuranosyl-, EINECS 226-893-9, 3XQD2MEW34, Adenine, 9-beta-D-arabinofuranosyl-, CI-673, 9H-Purin-6-amine, 9-beta-D-arabinofuranosyl-, NSC 247519, BRN 0624881, 6-Amino-9-beta-D-arabinofuranosylpurine, CHEBI:45327, 2-(6-Amino-purin-9-yl)-5-hydroxymethyl-tetrahydro-furan-3,4-diol, AI3-52821, VIDARABINE [MI], (2R,3S,4S,5R)-2-(6-amino-9H-purin-9-yl)-5-(hydroxymethyl)oxolane-3,4-diol, 9H-Purin-6-amine, 9beta-D-arabinofuranosyl-, CI 673, VIDARABINE [HSDB], 9H-Purin-6-amine, 9-.beta.-D-arabinofuranosyl-, Arabinofuranosyladenine, NSC-247519, NSC-757383, VIDARABINE [WHO-DD], (2R,3S,4S,5R)-2-(6-Aminopurin-9-yl)-5-(hydroxymethyl)oxolane-3,4-diol, alpha-Ara A, beta-Ara A, Ara A, 9-(beta-D-arabinofuranosyl)-9H-adenine, 9H-adenin-9-yl beta-D-arabinofuranoside, 9–D-arabinofuranosyl-9H-purin-6-amine, Armes, VIDARABINE [JAN], Vidarabinum (INN-Latin), 9-.beta.-D-Arabinofuranosyl-9H-purin-6-amine, Vira-A (TN), VIDARABINE [VANDF], VIDARABINE (MART.), VIDARABINE [MART.], ViraA, CHEBI:9978, alpha Ara A, beta Ara A, VIDARABINE [ORANGE BOOK], VIDARABINE (USP IMPURITY), VIDARABINE [USP IMPURITY], 9-beta-Arabinofuranosyladenine, VIDARABINE MONOHYDRATE [MI], Arabinoside, Adenine, 9-beta-D-Arabinofuranosyladenine monohydrate, 9-beta-D-Arabino furanosyl adenine monohydrate, 9 beta Arabinofuranosyladenine, alpha D Arabinofuranosyladenine, 9 beta D Arabinofuranosyladenine, 9-.BETA.-D-ARABINOFURANOSYLADENINE MONOHYDRATE, NSC 404241, 9H-Purin-6-amine, 9-beta-D-arabinofuranosyl-, monohydrate, Beta Ara-A, 9H-Purin-6-amine, 9-.beta.-D-arabinofuranosyl-, monohydrate, BETA-ARA-A, Adenine Arabinoside Anhydrous, 9-BETA-D-ARABINOADENOSINE, J05AB03, S01AD06, 9-beta-D-arabinofuranosyladenine Anyhydrous, 9-beta-D-Arabinofuranosyl-9H-purin-6-amine (9CI), 226-893-9, 678-339-4, (2R,3S,4S,5R)-2-(6-Amino-9H-purin-9-yl)-5-(hydroxymethyl)tetrahydrofuran-3,4-diol, Adenine 9-beta-D-arabinofuranoside, araA, 6-Amino-9-b-D-arabinofuranosylpurine, Vidarabine (Vira-A), Adenine 9-beta;-D-arabinofuranoside, CHEMBL1090, 9-(beta-D-Arabinofuranosyl)adenine, RAB, Vidarabine (monohydrate), MFCD00065471, (+)-Cyclaradine, SMR000471872, UNII-3XQD2MEW34, Vidarabine (Standard), Spectrum_001894, Spectrum2_001336, Spectrum3_000580, Spectrum4_000782, Spectrum5_001429, BSPBio_002000, KBioGR_001224, KBioSS_002424, MLS001066352, MLS001333133, MLS001333134, DivK1c_000191, SCHEMBL110914, SPECTRUM1500609, SPBio_001491, 9-ss-D-Arabinofuranosyladenine, GTPL4806, 9-ss -D-Arabinofuranosyladenine, 9-(b-D-Arabinofuranosyl)adenine, HMS500J13, HY-B0277R, KBio1_000191, KBio2_002418, KBio2_004986, KBio2_007554, KBio3_001500, Adenine 9-ss-D-arabinofuranoside, DTXSID80873976, 9-beta-D-arabinofuranosyl adenine, Adenine 9-|A-D-arabinofuranoside, NINDS_000191, Adenine 9-ss -D-arabinofuranoside, HMS1921K05, HMS2090F06, HMS2092C16, HMS2230N24, HMS3259I08, HMS3714I18, Pharmakon1600-01500609, BCP27778, HY-B0277, BDBM50144936, CCG-39634, HG1001, MSK156753, NSC757383, PDSP1_001036, PDSP2_001020, s1784, AKOS015919711, DB00194, DS-1755, NA06007, NC00547, IDI1_000191, SMP1_000312, NCGC00023673-08, NCGC00178869-01, NCGC00178869-02, NCGC00178869-10, 6-amino-9-(beta-D-arabinofuranosyl)purine, SBI-0051555.P002, Adenine 9-beta-D-arabinofuranoside, >=99%, NS00124064, SW199234-2, V0098, V0175, D06298, 9-.beta.-D-Arabinofuranosyl-9H-purine-6-amine, AB00430250-08, AB00430250-09, AB00430250_11, AB00430250_12, EN300-6477965, Q415107, SR-01000765435, SR-05000001737, SR-01000765435-2, SR-05000001737-1, BRD-K72093121-001-16-3, BRD-K72093121-001-17-1, (2R,3S,4S,5R)-2-(6-aminopurin-9-yl)-5-(hydroxymethyl)tetrahydrofuran-3,4-diol, Vidarabine;Ara-A;(2R,3S,4S,5R)-2-(6-Amino-9H-purin-9-yl)-5-(hydroxymethyl)tetrahydrofuran-3,4-diol

Vidarabine is widely used in antiviral research, particularly for studying herpes simplex virus (HSV) and varicella-zoster virus (VZV) inhibition. It serves as a reference standard in pharmacokinetic and pharmacodynamic studies. Additionally, it is employed in cell culture models to assess its impact on viral replication and host-cell toxicity. Researchers also utilize Vidarabine to explore nucleotide metabolism and DNA polymerase inhibition mechanisms.

Safety and Hazards

GHS Hazard Statements

• H361 (50%): Suspected of damaging fertility or the unborn child [Warning Reproductive toxicity]
• H361d (50%): Suspected of damaging the unborn child [Warning Reproductive toxicity]

Precautionary Statements

• P203, P280, P318, P405, and P501

Hazard Classes and Categories

• Repr. 2 (50%)
• Repr. 2 (50%)

If you are interested or have any questions, please contact us at support@atomfair.com

Disclaimer: Sold exclusively for laboratory research. Prohibited for commercial use, diagnostics, or human/animal applications. Buyers assume all compliance liability.